UPCC 05519: Single-Arm Study Of Carboplatin Weekly Taxane And Ramucirumab In Advanced NSCLC After Progressive Disease On Maintenance Pemetrexed And/Or Pembrolizumab
Enrolling By Invitation
18-100 years
All
Phase
2
49 participants needed
1 Location
Brief description of study
The purpose of this study is to determine if the combination of the three anti-cancer drugs carboplatin, paclitaxel, and ramucirumab is helpful in shrinking tumors or delaying tumor growth in participants with non-small cell lung cancer. This study will also assess whether it is safe to combine these drugs.
Participants for this study, will be recruited from the physician practices of the University of Pennsylvania.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: cancer
-
Age: Between 18 Years - 100 Years
-
Gender: All
Updated on
01 Aug 2024.
Study ID: 833759
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
